Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plan B Plaintiffs Expect to Face Court’s “Huge Deference” To FDA

This article was originally published in The Tan Sheet

Executive Summary

A recently filed federal lawsuit challenging FDA's approval for OTC distribution of Plan B may present good cause for contesting the drug's approval, but will likely face an uphill battle, the plaintiffs acknowledge

You may also be interested in...



FDA’s Plan B Approval Illegal, Unconstitutional, Federal Suit Says

FDA's approval for OTC distribution of Plan B emergency contraceptive violated the Food, Drug, and Cosmetic and Administrative Procedure acts, as well as the due process clause of the Constitution, according to an April 12 lawsuit seeking to overturn the approval

Plan B Pioneers OTC “Pharmacy Counter” Approval, Dual-Status Marketing

FDA's decision to approve emergency contraceptive Plan B for over-the-counter sale to women age 18 and older cracks open the door on a pharmacy-only, behind-the-counter model for nonprescription drug sales

FTC Views Testimonials As Efficacy Claims, Senior Attorney Warns

The Federal Trade Commission's senior staff attorney for advertising practices recommends firms stay away from using consumer testimonials to assert the benefits of their products

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS100432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel